Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma

Journal of the Medical Association of Thailand

Volumn 90, Issue 1, 2007, Pages 52-58

  Leecharoen, Sukanya ^a   Wangkaew, Suparaporn ^a   Louthrenoo, Worawit ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Chloroquine toxicity; Retinopathy; Rheumatoid arthritis; Scleroderma; Systemic lupus erythematosus

Indexed keywords

CHLOROQUINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; CREATININE CLEARANCE; DRUG ACCUMULATION; FEMALE; HUMAN; MALE; MEDICAL RECORD; OPHTHALMOLOGY; RETINA MACULA EDEMA; RETINOPATHY; RHEUMATOID ARTHRITIS; SCLERODERMA; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; EYE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 33846952135     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. th ed. Philadelphia: Elsevier; 2005: 877-99.
2. Rynes RI, Bernstein HN. Ophthalmologic safety profile of antimalarial drugs. Lupus 1993; 2(Suppl 1): S17-9.
3. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304.
4. Rynes RI. Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996; 5(Suppl 1): S73-4.
5. Cox NH, Paterson WD. Ocular toxicity of antimalarials in dermatology: a survey of current practice. Br J Dermatol 1994; 131: 878-82.
6. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12: 692-4.
7. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol 1999; 38: 934-7.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
12. Elman A, Gullberg R, Nilsson E, Rendahl I, Wachtmeister L. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol 1976; 5: 161-6.
13. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh) 1967; 92 (Suppl): 1-71.
14. Voipio H. Incidence of chloroquine retinopathy. Acta Ophthalmol (Copenh) 1966; 44: 349-54.
15. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75: 40-5.
16. Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13: 119-24.
17. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990; 25: 249-51.
18. nd ed. Edinberg: Livingstone; 1970.
19. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-82.
20. Neubauer AS, Samari-Kermani K, Schaller U, Welge-Lubetaen U, Rudolph G, Berninger T. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003; 87: 902-8.
21. Almony A, Garg S, Peters RK, Mamet R, Tsong J, Shibuya B, et al. Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. Br J Ophthalmol 2005; 89: 569-74.
22. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin 1999; 39: 49-57.